AUTHORS
Maria Victoria del Rosal, MD, Yuki Joyama, MD2, Stephanie Tuminello, PhD3, Sundar Jagannath, M.D.4, Samir Parekh, MD5, Emanuela Taioli, MD, PhD6, Santiago Thibaud, MD7
AFFILIATIONS
1 Icahn School Of Medicine at Mount Sinai, New York City, New York, United States
2 Icahn School Of Medicine at Mount Sinai, New York City, New York, United States
3 Icahn School Of Medicine at Mount Sinai, New York City, New York, United States
4 Icahn School Of Medicine at Mount Sinai, New York City, New York, United States
5 Icahn School Of Medicine at Mount Sinai, New York City, New York, United States
6 Icahn School Of Medicine at Mount Sinai, New York City, New York, United States
7 Icahn School Of Medicine at Mount Sinai, New York City, New York, United States
ABSTRACT
Introduction
Multiple myeloma (MM) is recognized as a World Trade Center (WTC)-related malignancy, with prior studies showing increased MM and precursor plasma cell disorder risk among WTC-exposed responders. However, whether WTC-exposed MM has distinct clinical or cytogenetic features remains unknown. This question is clinically relevant because translational studies in other WTC-associated cancers have linked exposure to inflammatory, epigenetic, and molecular features of aggressive disease. We therefore conducted a comprehensive clinical and cytogenetic characterization of WTC-exposed MM compared with non-WTC institutional controls.
Methods
We performed a retrospective single-institution cohort study of WTC-exposed newly-diagnosed MM (NDMM) patients (n=108) and non-WTC NDMM controls with diagnostic FISH data (n=2,097). WTC exposure was ascertained from clinical documentation and WTC Health Program records. We compared demographic features, age at diagnosis, FISH-defined cytogenetic abnormalities, 2025 IMS/IMWG high-risk disease, additional primary malignancies, and clinical outcomes. Regression models were adjusted for age, sex, and race as appropriate, with Benjamini-Hochberg correction across the main clinical/cytogenetic comparisons. PFS after frontline therapy (PFS1) and OS were evaluated among patients with longitudinal follow-up.
Results
Among 2,205 NDMM patients, WTC-exposed patients were more often male than controls (74.1% vs 53.7%; P<.001), consistent with the sex distribution of the WTC responder population. Racial distribution was similar between groups (P=.801). MM was diagnosed a median of 16.3 years after WTC exposure (range 3.6-24.1 years). WTC-exposed patients were younger at MM diagnosis than controls (mean, 58.3 vs 63.0 years). After adjustment for sex and race, WTC exposure remained associated with diagnosis 4.6 years earlier (95% CI, −6.7 to −2.5; P<.001; FDR q<.001). This association persisted when restricted to the shared age range of both cohorts (adjusted difference, −3.9 years; 95% CI, −5.9 to −2.0; P<.001). High-risk cytogenetics were more frequent in WTC-exposed patients than controls (21.3% vs 14.8%; adjusted OR, 1.65; 95% CI, 1.02-2.67; P=.04; FDR q=.04). 17p deletion/TP53 loss was numerically enriched in WTC-exposed patients (12.0% vs 7.9%), although this association did not reach statistical significance (adjusted OR, 1.71; 95% CI, 0.93–3.16; P=.08). Additional primary malignancies were markedly more common in WTC-exposed patients (31.5% vs 18.7%; adjusted RR, 2.05; 95% CI, 1.53-2.75; P<.001; FDR q<.001), including after exclusion of nonmelanoma skin cancer (26.9% vs 16.5%; adjusted RR, 2.00; 95% CI, 1.44-2.78; P<.001). Among patients with at least one additional primary malignancy, WTC-exposed patients were more likely to have two or more additional primary malignancies than controls (41.2% vs 17.8%; P=.003). Exploratory survival analyses showed no significant difference in adjusted PFS1 or OS.
Conclusions
In the largest WTC-exposed MM cohort characterized to date, WTC-exposed patients were diagnosed at younger age, had higher rates of high-risk cytogenetics at diagnosis, and additional primary malignancies than non-WTC controls. These findings suggest that WTC-exposed MM may represent a clinically relevant exposure-associated phenotype, rather than simply excess MM incidence. For treating clinicians, WTC exposure history may be relevant to risk assessment, review of prior and subsequent malignancies, and future surveillance strategies. Prospective molecular and exposomic studies are needed to validate these findings and define the biology underlying this phenotype.
DISCLOSURES
Maria Victoria del Rosal, MD: No relevant conflicts of interest to declare.